Telmidip (Telmisartan/Amlodipine): A Fixed-Dose Combination for Hypertension

Telmidip is a fixed-dose combination of Telmisartan (an angiotensin receptor blocker) and Amlodipine (a dihydropyridine calcium-channel blocker). It is indicated for the treatment of hypertension, either alone or with other antihypertensive agents. It may also be used as initial therapy for patients likely to need multiple drugs to control their blood pressure. It belongs to the therapeutic class of Combined antihypertensive preparations.

How Telmidip Works (Pharmacology)

Telmidip combines two different mechanisms to lower blood pressure:

• Telmisartan (Angiotensin Receptor Blocker - ARB):
  • It is a specific angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor.
  • Angiotensin II is a powerful vasoconstrictor and stimulates the release of aldosterone, both of which increase blood pressure.
  • By blocking this effect, Telmisartan dilates blood vessels and reduces blood pressure without affecting the pulse rate.
• Amlodipine (Calcium-Channel Blocker - CCB):
  • It inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle.
  • This action causes peripheral arterial vasodilation, which reduces peripheral vascular resistance and, as a result, lowers blood pressure.

Key Indications & Benefits

Telmidip is indicated for the treatment of hypertension:

• As monotherapy in patients who require more than one drug to achieve their blood pressure goals.
• As add-on therapy for patients whose blood pressure is not adequately controlled with either amlodipine or telmisartan alone.
• As replacement therapy for patients already taking amlodipine and telmisartan from separate tablets.

Dosage & Administration

Dosage must be individualized. The tablets should be taken once daily. Always consult a registered physician for specific dosage instructions.

• Initial Therapy:
  • Usual starting dose: 40/5 mg once daily.
  • Patients needing a larger reduction: 80/5 mg once daily.
  • Initial therapy is not recommended for patients 75 years or older or those with hepatic impairment.
• Replacement Therapy:
  • Patients can be switched to the same component doses once daily.
• Maximum recommended dose:80/10 mg once daily.

Important Considerations & Warnings

It is crucial to discuss your full medical history with your doctor before taking Telmidip.

Contraindications:

• Known hypersensitivity to any component of the product.
• Pregnancy and lactation.
• Biliary obstructive disorders, severe hepatic impairment, hypotension, cardiogenic shock, and left ventricular outflow tract obstruction.

Side Effects:

• Common side effects include dizziness, peripheral edema, headache, and fatigue.
• Other reported side effects include migraine, vertigo, bradycardia, palpitations, hypotension, cough, abdominal pain, diarrhea, and nausea.

Pregnancy & Lactation:

• Pregnancy: Classified as Category C (first trimester) and Category D (second and third trimesters) due to the risk of injury and death to the developing fetus. Avoid fetal exposure.
• Lactation: It is not known if telmisartan and amlodipine are excreted in human milk. Discontinue nursing or discontinue the drug, considering its importance to the mother.

Precautions & Warnings:

• Fetal/Neonatal Exposure: Avoid use during pregnancy.
• Hypotension: Correct any volume or salt depletion before initiating therapy.
• Renal/Hepatic Impairment: Titrate the dose slowly in patients with hepatic or severe renal impairment. Initial therapy is not recommended for hepatically impaired patients or those ≥75 years old.
• Heart Failure: Monitor for worsening heart failure.
• Myocardial Infarction: Uncommonly, initiating a CCB may precipitate myocardial infarction or increased angina in patients with severe obstructive coronary artery disease.
• Dual Therapy: Avoid the concomitant use of an ACE inhibitor and an angiotensin receptor blocker.

Drug Interactions:

• Telmisartan: No clinically significant interactions with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen.
• Amlodipine: Safely administered with many common drugs. No clinically relevant effects with cimetidine, grapefruit juice, or sildenafil.
• CYP2C19: Telmisartan may inhibit the metabolism of drugs metabolized by this enzyme.

Overdose Effects

• Telmisartan: Overdosage may cause hypotension, dizziness, and tachycardia. Treatment is symptomatic and supportive. Telmisartan is not removed by hemodialysis.
• Amlodipine: Overdosage can lead to excessive vasodilation with marked hypotension and possibly reflex tachycardia. Treatment involves active cardiac and respiratory monitoring, blood pressure measurements, and supportive care. Amlodipine is not removed by hemodialysis.

Storage Conditions

Do not store above 30°C. Protect from light and high humidity. Keep out of the reach of children.